MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

MDT

84.09

-0.06%↓

VEEV

226.15

+0.17%↑

A

105.84

-0.02%↓

WBA

10.99

+0.09%↑

CHE

550.42

-2.1%↓

Search

Amphastar Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

23.93 -0.08

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

23.47

Максимум

24.11

Ключови измерители

By Trading Economics

Приходи

-2.5M

38M

Продажби

-1.8M

187M

P/E

Средно за сектора

7.68

57.333

EPS

0.92

Марж на печалбата

20.304

Служители

2,028

EBITDA

-3.8M

65M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+53.72% upside

Дивиденти

By Dow Jones

Следващи печалби

7.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-436M

1.1B

Предишно отваряне

24.01

Предишно затваряне

23.93

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Amphastar Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

24.04.2025 г., 23:54 ч. UTC

Горещи акции

Stocks to Watch: Alphabet, Intel, AppFolio

24.04.2025 г., 23:51 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.04.2025 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24.04.2025 г., 23:37 ч. UTC

Топ новини

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24.04.2025 г., 23:36 ч. UTC

Топ новини

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24.04.2025 г., 23:13 ч. UTC

Топ новини
Печалби

Google's Earnings Power Holds Up in Global Turbulence -- Update

24.04.2025 г., 23:09 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24.04.2025 г., 23:02 ч. UTC

Придобивния, сливания и поглъщания

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24.04.2025 г., 22:51 ч. UTC

Топ новини
Придобивния, сливания и поглъщания

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24.04.2025 г., 22:48 ч. UTC

Топ новини

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24.04.2025 г., 22:47 ч. UTC

Пазарно говорене

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24.04.2025 г., 22:38 ч. UTC

Пазарно говорене
Печалби

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24.04.2025 г., 22:24 ч. UTC

Печалби

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24.04.2025 г., 22:24 ч. UTC

Пазарно говорене
Печалби

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24.04.2025 г., 22:23 ч. UTC

Печалби

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене
Печалби

Global Equities Roundup: Market Talk

24.04.2025 г., 22:11 ч. UTC

Пазарно говорене
Печалби

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24.04.2025 г., 22:09 ч. UTC

Топ новини
Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24.04.2025 г., 22:00 ч. UTC

Пазарно говорене
Печалби

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24.04.2025 г., 21:39 ч. UTC

Топ новини

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24.04.2025 г., 21:24 ч. UTC

Топ новини
Печалби

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24.04.2025 г., 21:24 ч. UTC

Топ новини
Печалби

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24.04.2025 г., 21:23 ч. UTC

Топ новини
Печалби

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24.04.2025 г., 21:04 ч. UTC

Печалби

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24.04.2025 г., 21:03 ч. UTC

Печалби

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24.04.2025 г., 21:02 ч. UTC

Печалби

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Сравнение с други в отрасъла

Ценова промяна

Amphastar Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

53.72% нагоре

12-месечна прогноза

Среден 37 USD  53.72%

Висок 45 USD

Нисък 31 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Amphastar Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

2

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

23.52 / 24.16Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.